Home › Companies › Maravai LifeSciences Holdings, Inc. › 2024-2025

Maravai LifeSciences Holdings, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and Maravai LifeSciences Holdings, Inc.’s Form 8-K, filed 2025-05-28 (Item 5.07 on EDGAR). Page generated 04 October 2026.

7Ballot items
185Asset managers
1,122Fund votes
2025-05-22Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Maravai LifeSciences Holdings, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by Maravai LifeSciences Holdings, Inc.

These tallies are Maravai LifeSciences Holdings, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-28 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Maravai LifeSciences Holdings, Inc. — official shareholder meeting results, meeting held 2025-05-22
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Sean Cunningham	185,635,895	--	--	23,897,811	22,152,617	Majority: yes
Elect Director: John DeFord, Ph.D.	195,101,055	--	--	14,432,651	22,152,617	Majority: yes
Elect Director: Jessica Hopfield, Ph.D.	185,887,446	--	--	23,646,260	22,152,617	Majority: yes
Elect Director: Murali K. Prahalad, Ph.D.	189,100,818	--	--	20,432,888	22,152,617	Majority: yes
Proposal 2: Proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025. The appointment of Ernst & Young LLP as the Company's independent registered public accoun	230,018,925	457,700	1,209,699	--	--	Passed
Proposal 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. The Company's shareholders approved, on a non-binding and adviso	169,521,411	37,367,937	2,644,358	--	22,152,617	Majority: yes

Source: Maravai LifeSciences Holdings, Inc., Form 8-K, filed with the SEC on 2025-05-28 — read the filing on EDGAR.

How asset managers voted at the Maravai LifeSciences Holdings, Inc. 2024-2025 meeting

Each item below shows how the 185 asset managers that disclosed a Maravai LifeSciences Holdings, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF MARAVAI'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2025-05-22.

Combines 7 wordings of this item as funds reported it.

82% Majority: yes · of votes cast

FOR 82%AGAINST 18%

FOR: 169,521,411AGAINST: 37,367,937

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Proposal 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. The Company's shareholde”): 169,521,411 for, 37,367,937 against, per its Form 8-K filed 2025-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 183 asset managers below cast 82% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the company's reported shares outstanding.

FOR 81%AGAINST 18%

FOR: 80.8%AGAINST: 18.0%ABSTAIN: 1.2%

Largest asset managers voting on “TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF MARAVAI'S NAMED EXECUTIVE OFFICERS.” at Maravai LifeSciences Holdings, Inc., 2024-2025
Asset manager	For	Against	Abstain	Vote
GTCR LLC	130,834,085	0	0	For
12 West Capital Management LP	12,339,614	0	0	For
Vanguard	11,818,703	64	0	For
BlackRock	130,351	8,170,318	0	Against
BRAIDWELL LP	0	6,229,366	0	Against
MACKENZIE FINANCIAL CORP	0	6,113,622	0	Against
Columbia Threadneedle	3,095,759	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,307,242	0	0	For
Renaissance	0	2,288,859	0	Against
Fidelity	2,082,896	50,355	0	For
Two Sigma	0	2,030,402	0	Against
Charles Schwab	0	1,896,815	0	Against
Royce	0	0	1,551,719	Abstain
State Street	1,265,326	39,808	0	For
Eversept Partners, LP	0	0	942,454	Abstain
Lazard	0	911,833	0	Against
SYSTEMATIC FINANCIAL MANAGEMENT LP	0	871,926	0	Against
Dimensional	0	866,027	0	Against
Northern Trust	813,245	16,350	0	For
PenderFund Capital Management Ltd.	814,565	0	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	0	565,150	0	Against
Orion Porfolio Solutions, LLC	0	495,835	0	Against
Invesco	0	408,250	0	Against
MELLON INVESTMENTS Corp	0	394,130	0	Against
Point72	0	332,415	0	Against

Showing the 25 largest of 183 asset managers. See all 183 in the interactive database.

2. To elect four nominees to the Board of Directors (3-year term expiring in 2028): Jessica Hopfield, PhD

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-22.

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 185,887,446WITHHELD: 23,646,260

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Jessica Hopfield, Ph.D.”): 185,887,446 for, 23,646,260 withheld, per its Form 8-K filed 2025-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 51 asset managers below cast 100% of the shares they voted on this item FOR (22,013,149 for, 0 against).

FOR 81%ABSTAIN 19%

FOR: 22,013,149 (81.2%)ABSTAIN: 5,095,224 (18.8%)

Largest asset managers voting on “To elect four nominees to the Board of Directors (3-year term expiring in 2028): Jessica Hopfield, PhD” at Maravai LifeSciences Holdings, Inc., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	11,452,572	0	For
BlackRock	4,310,457	0	For
Columbia Threadneedle	0	3,095,759	Abstain
Fidelity	2,127,430	0	For
Royce	1,521,430	0	For
Charles Schwab	948,400	0	For
Dimensional	0	774,402	Abstain
Equitable	177,293	141,420	For
MFS	0	229,452	Abstain
Global X	220,699	0	For
Lazard	0	197,090	Abstain
QUANTITATIVE MASTER SERIES LLC	190,588	0	For
TIAA	189,391	0	For
Transamerica	189,100	0	For
Invesco	0	178,249	Abstain
Lincoln Financial	81,900	79,218	For
VELA Funds	149,634	0	For
TIFF INVESTMENT PROGRAM	147,267	0	For
RBC FUNDS TRUST	0	70,940	Abstain
Northern Trust	67,553	0	For
ProShares	0	50,023	Abstain
John Hancock	0	41,238	Abstain
JPMorgan	41,011	0	For
Goldman Sachs	0	39,693	Abstain
Pacific Life	34,188	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

3. To elect four nominees to the Board of Directors (3-year term expiring in 2028): John DeFord, PhD

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-22.

Combines 2 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%

FOR: 195,101,055WITHHELD: 14,432,651

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: John DeFord, Ph.D.”): 195,101,055 for, 14,432,651 withheld, per its Form 8-K filed 2025-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 51 asset managers below cast 100% of the shares they voted on this item FOR (21,142,763 for, 0 against).

FOR 78%ABSTAIN 22%

FOR: 21,142,763 (78.0%)ABSTAIN: 5,965,610 (22.0%)

Largest asset managers voting on “To elect four nominees to the Board of Directors (3-year term expiring in 2028): John DeFord, PhD” at Maravai LifeSciences Holdings, Inc., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	11,452,572	0	For
BlackRock	0	4,310,457	Abstain
Columbia Threadneedle	3,095,759	0	For
Fidelity	2,077,075	50,355	For
Royce	1,521,430	0	For
Charles Schwab	948,400	0	For
Dimensional	0	774,402	Abstain
Equitable	0	318,713	Abstain
MFS	229,452	0	For
Global X	220,699	0	For
Lazard	0	197,090	Abstain
QUANTITATIVE MASTER SERIES LLC	0	190,588	Abstain
TIAA	189,391	0	For
Transamerica	189,100	0	For
Invesco	178,249	0	For
Lincoln Financial	152,058	9,060	For
VELA Funds	149,634	0	For
TIFF INVESTMENT PROGRAM	147,267	0	For
RBC FUNDS TRUST	70,940	0	For
Northern Trust	67,553	0	For
ProShares	50,023	0	For
John Hancock	41,238	0	For
JPMorgan	41,011	0	For
Goldman Sachs	39,693	0	For
Pacific Life	0	34,188	Abstain

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

4. To elect four nominees to the Board of Directors (3-year term expiring in 2028): Murali K. Prahalad, PhD

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-22.

Combines 2 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 189,100,818WITHHELD: 20,432,888

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Murali K. Prahalad, Ph.D.”): 189,100,818 for, 20,432,888 withheld, per its Form 8-K filed 2025-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 51 asset managers below cast 100% of the shares they voted on this item FOR (25,317,639 for, 0 against).

FOR 93%

FOR: 25,317,639 (93.4%)ABSTAIN: 1,790,734 (6.6%)

Largest asset managers voting on “To elect four nominees to the Board of Directors (3-year term expiring in 2028): Murali K. Prahalad, PhD” at Maravai LifeSciences Holdings, Inc., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	11,452,572	0	For
BlackRock	4,310,457	0	For
Columbia Threadneedle	3,095,759	0	For
Fidelity	2,127,430	0	For
Royce	1,521,430	0	For
Charles Schwab	948,400	0	For
Dimensional	0	774,402	Abstain
Equitable	177,293	141,420	For
MFS	0	229,452	Abstain
Global X	220,699	0	For
Lazard	0	197,090	Abstain
QUANTITATIVE MASTER SERIES LLC	190,588	0	For
TIAA	189,391	0	For
Transamerica	189,100	0	For
Invesco	178,249	0	For
Lincoln Financial	81,900	79,218	For
VELA Funds	149,634	0	For
TIFF INVESTMENT PROGRAM	147,267	0	For
RBC FUNDS TRUST	0	70,940	Abstain
Northern Trust	67,553	0	For
ProShares	0	50,023	Abstain
John Hancock	0	41,238	Abstain
JPMorgan	41,011	0	For
Goldman Sachs	0	39,693	Abstain
Pacific Life	34,188	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

5. To elect four nominees to the Board of Directors (3-year term expiring in 2028): Sean Cunningham

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2025-05-22.

Combines 2 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 185,635,895WITHHELD: 23,897,811

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Elect Director: Sean Cunningham”): 185,635,895 for, 23,897,811 withheld, per its Form 8-K filed 2025-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 51 asset managers below cast 100% of the shares they voted on this item FOR (24,921,483 for, 0 against).

FOR 92%8%

FOR: 24,921,483 (91.9%)ABSTAIN: 2,186,890 (8.1%)

Largest asset managers voting on “To elect four nominees to the Board of Directors (3-year term expiring in 2028): Sean Cunningham” at Maravai LifeSciences Holdings, Inc., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	11,452,572	0	For
BlackRock	4,310,457	0	For
Columbia Threadneedle	3,095,759	0	For
Fidelity	2,127,296	134	For
Royce	1,521,430	0	For
Charles Schwab	948,400	0	For
Dimensional	0	774,402	Abstain
Equitable	177,293	141,420	For
MFS	0	229,452	Abstain
Global X	220,699	0	For
Lazard	0	197,090	Abstain
QUANTITATIVE MASTER SERIES LLC	190,588	0	For
TIAA	0	189,391	Abstain
Transamerica	189,100	0	For
Invesco	178,249	0	For
Lincoln Financial	0	161,118	Abstain
VELA Funds	149,634	0	For
TIFF INVESTMENT PROGRAM	147,267	0	For
RBC FUNDS TRUST	0	70,940	Abstain
Northern Trust	0	67,553	Abstain
ProShares	0	50,023	Abstain
John Hancock	0	41,238	Abstain
JPMorgan	41,011	0	For
Goldman Sachs	0	39,693	Abstain
Pacific Life	34,188	0	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

6. To ratify the appointment of Ernst & Young LLP as Maravai's independent registered public accounting firm for the year ending December 31, 2025.

AUDIT-RELATEDCompany result: Passed

Meeting held 2025-05-22.

99.8% Passed · of votes cast

FOR 99.8%

FOR: 230,018,925AGAINST: 457,700

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Proposal 2: Proposal to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025. The appointment of Ernst & Young LLP as the Compan”): 230,018,925 for, 457,700 against — passed, per its Form 8-K filed 2025-05-28 (Item 5.07). Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 51 asset managers below cast 100% of the shares they voted on this item FOR (27,108,373 for, 0 against).

FOR 100%

FOR: 27,108,373 (100.0%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as Maravai's independent registered public accounting firm for ” at Maravai LifeSciences Holdings, Inc., 2024-2025
Asset manager	For	Vote
Vanguard	11,452,572	For
BlackRock	4,310,457	For
Columbia Threadneedle	3,095,759	For
Fidelity	2,127,430	For
Royce	1,521,430	For
Charles Schwab	948,400	For
Dimensional	774,402	For
Equitable	318,713	For
MFS	229,452	For
Global X	220,699	For
Lazard	197,090	For
QUANTITATIVE MASTER SERIES LLC	190,588	For
TIAA	189,391	For
Transamerica	189,100	For
Invesco	178,249	For
Lincoln Financial	161,118	For
VELA Funds	149,634	For
TIFF INVESTMENT PROGRAM	147,267	For
RBC FUNDS TRUST	70,940	For
Northern Trust	67,553	For
ProShares	50,023	For
John Hancock	41,238	For
JPMorgan	41,011	For
Goldman Sachs	39,693	For
Pacific Life	34,188	For

Showing the 25 largest of 51 asset managers. See all 51 in the interactive database.

7. To approve, on a non-binding advisory basis, the compensation of Maravai's named executive officers.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2024-05-23 (outside the 2024-2025 season's 1 July to 30 June window; reported in this season's filings).

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 223,303,654AGAINST: 4,747,004

Maravai LifeSciences Holdings, Inc.’s own tally for this item (“Proposal 3: Proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as disclosed in the Company's proxy statement for the Annual Meeting. The Company's shareholde”): 223,303,654 for, 4,747,004 against, per its Form 8-K filed 2024-05-28 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Share-of-outstanding not shown: votes cast exceed the reported share count, which usually means multiple share classes with different voting rights.

The 2 asset managers below cast 0% of the shares they voted on this item FOR (0 for, 849 against).

AGAINST 100%

AGAINST: 849 (100.0%)

Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of Maravai's named executive officers.” at Maravai LifeSciences Holdings, Inc., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
COLDSTREAM CAPITAL MANAGEMENT INC	0	849	0	0	Against
Echo45 Advisors LLC	0	0	0	0	--

Largest Maravai LifeSciences Holdings, Inc. shareholders voting in 2024-2025

Ranked by the number of Maravai LifeSciences Holdings, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 143,425,000 shares outstanding at the time of that meeting.

Top Maravai LifeSciences Holdings, Inc. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	GTCR LLC	91.22%
2	12 West Capital Management LP	8.60%
3	Vanguard	8.24%
4	BlackRock	5.79%
5	BRAIDWELL LP	4.34%
6	MACKENZIE FINANCIAL CORP	4.26%
7	Columbia Threadneedle	2.16%
8	GEODE CAPITAL MANAGEMENT, LLC	1.61%
9	Renaissance	1.60%
10	Fidelity	1.49%

Reported Maravai LifeSciences Holdings, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Maravai LifeSciences Holdings, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
GTCR	14.05%	DEF14A
Vanguard Group	8.13%	13F
West Capital Management LP	8.08%	DEF14A
Stuart Feldman	7.21%	13G
BlackRock	6.66%	13F
12 West Capital Management LP	5.06%	13G
Renaissance Technologies	2.87%	13F
State Street	1.90%	13F
Morgan Stanley	1.77%	13F
Two Sigma	1.00%	13F

Percentages above are of 143,425,000 shares outstanding, as reported by Maravai LifeSciences Holdings, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Maravai LifeSciences Holdings, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At Maravai LifeSciences Holdings, Inc.'s shareholder meeting held 2025-05-22, in the 2024-2025 proxy season, 185 asset managers reported how they voted on 7 ballot items in their SEC Form N-PX filings, covering 1,122 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON A NON-BINDING ADVISORY BASIS, THE COMPENSATION OF MARAVAI'S NAMED EXECUTIVE… — FOR was 82% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Maravai LifeSciences Holdings, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-28.

Maravai LifeSciences Holdings, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.